Public Market Listing
2595 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (3 total) 3 Total Assets
0 Approved
1 Phase 3 / Filed
2 Phase 1–2 / Early
2 Diseases
Disease: All diseases (3) Non-Small Cell Lung Cancer (3) Pancreatic Ductal Adenocarcinoma (1)
Stage: All stages (3) Approved / Phase 4 (0) Phase 3 / Filed (1) Phase 2 Phase 1 / Preclinical
Quick filter: All (3) Non-Small Cell Lung Cancer (3) Pancreatic Ductal Adenocarcinoma (1)
Showing 3 of 3 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 KRAS G12D Small molecule
Non-Small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma
Phase 2 KRAS G12C Small molecule
Non-Small Cell Lung Cancer
Phase 1/2 pan-RAS Small molecule
Non-Small Cell Lung Cancer
Upcoming events (15 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (9) April 2027 (1) GFH375 Phase 2 NSCLC (Advanced Non-small Cell Lung Cancer) Est. primary completion 2027-04-30 ·
NCT07554859 ·
CT.gov ↗ What to watch
June 2027 (4) GFH375 Phase 2 Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS Est. primary completion 2027-06 ·
NCT07644559 ·
CT.gov ↗ What to watch
GFH375 Phase 2 Non-Small Cell Lung Cancer Est. primary completion 2027-06 ·
NCT07659782 ·
CT.gov ↗ What to watch
GFH375 Phase 2 Colorectal Cancer Est. primary completion 2027-06 ·
NCT07659795 ·
CT.gov ↗ What to watch
GFH375 Phase 3 Metastatic Pancreatic Cancer Est. primary completion 2027-06 ·
NCT07262567 ·
CT.gov ↗ What to watch
July 2027 (2) GFH375 Phase 1/2 Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer) Est. primary completion 2027-07 ·
NCT07259590 ·
CT.gov ↗ What to watch
GFH276 Phase 1/2 Cancer, PDAC, CRC (Colorectal Cancer), NSCLC Est. primary completion 2027-07-30 ·
NCT07198321 ·
CT.gov ↗ What to watch
November 2027 (1) GFH276 Phase 1/2 Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation Est. primary completion 2027-11 ·
NCT07678593 ·
CT.gov ↗ What to watch
December 2027 (1) GFH276 Phase 1/2 RAS Mutation, Non-small Cell Lung Cancer (NSCLC) Est. primary completion 2027-12 ·
NCT07846358 ·
CT.gov ↗ What to watch
2028 (5) April 2028 (1) Est. primary completion 2028-04-30 ·
NCT07915921 ·
CT.gov ↗ What to watch
July 2028 (1) GFH375 Phase 1/2 KRAS G12D Mutations, Advanced Solid Tumors Est. primary completion 2028-07-31 ·
NCT06500676 ·
CT.gov ↗ What to watch
August 2028 (1) GFH375 + GFH276 Phase 2 Pancreatic Cancer Est. primary completion 2028-08-31 ·
NCT07784374 ·
CT.gov ↗ What to watch
November 2028 (1) GFH375 Phase 3 Colorectal Cancer Est. primary completion 2028-11 ·
NCT07913360 ·
CT.gov ↗ What to watch
December 2028 (1) GFH375 Phase 1/2 Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS Est. primary completion 2028-12 ·
NCT07020221 ·
CT.gov ↗ What to watch
2030 (1) June 2030 (1) GFH375 Phase 3 KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer) Est. primary completion 2030-06-30 ·
NCT07668752 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Financial reports Quarterly & interim (1)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-H1 $12M — — $96M report ↗
Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $14M $46M — $94M report ↗
GenFleet Therapeutics reported revenue of $14.47M, up 38.2% YoY, R&D spend of $46.21M, up 4.3% YoY, and a quarterly net burn of $94.31M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2023-FY $10M $44M — $72M report ↗